Its been almost twenty years since Stuart Weisbrod and Jacob Gottlieb worked together at Merlin which Weisbrod co-founded in 1988. Merlin is an investment group that focuses primarily on the healthcare field. Gottlieb was hired on as a portfolio manager in 2000 and although they had many years of success, they closed in 2007 and gave their investors all the money back.
Stuart Weisbrod is a very educated man. He received a BA in Chemistry from Colgate University in 1975, an MBA in Finance from Columbia University in 1986, and a PhD in Biochemistry from Princeton in 1980. Besides his educational career, Weisbord has been successful in his business endeavors as well. Besides co-founding Merlin in 1988, he has also found victories in his investment deals in the healthcare and biochemistry fields when he has partnered with companies like Merrill Lynch and Oracle Partners, among others.
Since the closing of Merlin, Weisbroad and Gottlieb created new investment companies. Weisbrod opened Iguana Healthcare Partners which is another investment firm that focuses on healthcare, biotechnology, and pharmaceutical companies. Gottlieb created Visium Asset Management in 2008. Although he managed to grow Visium from $300 million to $2.5 billion, they eventually had to close in 2016 due to charges brought from the SEC claiming insider trading and mismarking. Gottlieb has never been charged with anything and he continues to work as CEO at Visium, returning money to investors.
Altium Capital is where Gottlieb will be going next. Altium Capital has made its first investment of 5.61% at Oramed Pharmaceuticals, Inc. Ormaed has been in the healthcare industry since 2006. Their newest ground-breaking product is insulin in tablet form which will keep patients from injecting it every time that they need it. Until now, it has been almost impossible to keep insulin working in tablet form. Not only is it easier for patients to take, but it is more cost effective for patients.
Although its been nearly two decades since Weisbrod and Gottlieb have worked in the same office, hopefully the healthcare investment sector will see some interesting things happen soon from these two successful investors.